Research for new drugs for elimination of onchocerciasis in Africa

Abegunde, 2016, Doxycycline plus ivermectin versus ivermectin alone for treatment of patients with onchocerciasis, Cochrane. Database. Syst. Rev., 1, CD011146 African Programme for Onchocerciasis Control (APOC), 2009 African Programme for Onchocerciasis Control (APOC), 2010 African Programme for Onchocerciasis Control (APOC), 2010, Conceptual and operational framework of onchocerciasis elimination with ivermectin treatment African Programme for Onchocerciasis Control (APOC), 2011 African Programme for Onchocerciasis Control (APOC), 2012 African Programme for Onchocerciasis Control (APOC), 2012 African Programme for Onchocerciasis Control (APOC), 2013 African Programme for Onchocerciasis Control (APOC), 2014 African Programme for Onchocerciasis Control (APOC), 2015 African Programme for Onchocerciasis Control (APOC), 2015, African programme for onchocerciasis control: progress report, 2014-2015, Wkly. Epidemiol. Rec., 90, 661 Ajayi, 2013, Assessing resources for implementing a community directed intervention (CDI) strategy in delivering multiple health interventions in urban poor communities in Southwestern Nigeria: a qualitative study, Infect. Dis. Poverty, 2, 25, 10.1186/2049-9957-2-25 Al-Qubati, 1994, The first use of ivermectin for the treatment of onchocerciasis in Yemen, Trans. R. Soc. Trop. Med. Hyg., 88, 343, 10.1016/0035-9203(94)90109-0 Al-Qubati, 1997, Onchodermatitis (sowda) in patients in Yemen. Clinical and histologic course after treatment with ivermectin, Sante, 7, 391 Ali, 2002, Immunocompetence may be important in the effectiveness of Mectizan (ivermectin) in the treatment of human onchocerciasis, Acta Trop., 84, 49, 10.1016/S0001-706X(02)00117-1 Andy, 1981, Loasis as a possible trigger of African endomyocardial fibrosis: a case report from Nigeria, Acta Trop., 38, 179 Anonymous, 2013, Progress towards eliminating onchocerciasis in the WHO region of the Americas: verification by WHO of elimination of transmission in Colombia, Wkly. Epidemiol. Rec., 88, 381 Anonymous, 2015, Progress toward eliminating onchocerciasis in the WHO region of the Americas: verification of elimination of transmission in Mexico, Wkly. Epidemiol. Rec., 90, 577 Awadzi, 1980, The chemotherapy of onchocerciasis II. Quantitation of the clinical reaction to microfilaricides, Ann. Trop. Med. Parasitol., 74, 189, 10.1080/00034983.1980.11687330 Awadzi, 1995, The chemotherapy of onchocerciasis XX: ivermectin in combination with albendazole, Trop. Med. Parasitol., 46, 213 Awadzi, 1999, The effects of high-dose ivermectin regimens on Onchocerca volvulus in onchocerciasis patients, Trans. R. Soc. Trop. Med. Hyg., 93, 189, 10.1016/S0035-9203(99)90305-X Awadzi, 2004, Thirty-month follow-up of sub-optimal responders to multiple treatments with ivermectin, in two onchocerciasis-endemic foci in Ghana, Ann. Trop. Med. Parasitol., 98, 359, 10.1179/000349804225003442 Awadzi, 2004, An investigation of persistent microfilaridermias despite multiple treatments with ivermectin, in two onchocerciasis-endemic foci in Ghana, Ann. Trop. Med. Parasitol., 98, 231, 10.1179/000349804225003253 Awadzi, 1990, Reactions to ivermectin treatment in onchocerciasis patients, Acta Leiden., 59, 193 Awadzi, 2003, The co-administration of ivermectin and albendazole–safety, pharmacokinetics and efficacy against Onchocerca volvulus, Ann. Trop. Med. Parasitol., 97, 165, 10.1179/000349803235001697 Awadzi, 1992, Diethylcarbamazine in the treatment of patients with onchocerciasis, Br. J. Clin. Pharmacol., 34, 281, 10.1111/j.1365-2125.1992.tb05632.x Awadzi, 2014, A randomized, single-ascending-dose, ivermectin-controlled, double-blind study of moxidectin in onchocerca volvulus infection, PLoS.Negl. Trop. Dis., 8, e2953, 10.1371/journal.pntd.0002953 Bakajika, 2013, Is O. volvulus suboptimal response to ivermectin a result of selection under ivermectin pressure? Insights from a study comparing ivermectin and moxidectin in areas without prior ivermectin mass treatment, Am. J. Trop. Med. Hyg., 89 Basanez, 2009, Onchocerca-Simulium interactions and the population and evolutionary biology of Onchocerca volvulus, Adv. Parasitol., 68, 263, 10.1016/S0065-308X(08)00611-8 Basanez, 2008, Effect of single-dose ivermectin on Onchocerca volvulus: a systematic review and meta-analysis, Lancet Infect. Dis., 8, 310, 10.1016/S1473-3099(08)70099-9 Basanez, 2001, Models for the population biology and control of human onchocerciasis, Trends Parasitol., 17, 430, 10.1016/S1471-4922(01)02013-X Benton, 1998, The onchocerciasis control program in West Africa (OCP): essential characteristics, Sante, 8, 26 Bird, 1980, Changes in visual function and in the posterior segment of the eye during treatment of onchocerciasis with diethylcarbamazine citrate, Br. J. Ophthalmol., 64, 191, 10.1136/bjo.64.3.191 Boatin, 2008, The onchocerciasis control programme in West Africa (OCP), Ann. Trop. Med. Parasitol., 102, 13, 10.1179/136485908X337427 Boatin, 2006, Control of onchocerciasis, Adv. Parasitol., 61, 349, 10.1016/S0065-308X(05)61009-3 Bosshardt, 1993, Prophylactic activity of tetracycline against Brugia pahangi infection in jirds (Meriones unguiculatus), J. Parasitol., 79, 775, 10.2307/3283620 Boussinesq, 2006, Loiasis, Ann. Trop. Med. Parasitol., 100, 715, 10.1179/136485906X112194 Boussinesq, 2003, Clinical picture, epidemiology and outcome of Loa-associated serious adverse events related to mass ivermectin treatment of onchocerciasis in Cameroon, Filaria. J., 2, S4, 10.1186/1475-2883-2-S1-S4 Boussinesq, 1998, Three probable cases of Loa loa encephalopathy following ivermectin treatment for onchocerciasis, Am. J. Trop. Med. Hyg., 58, 461, 10.4269/ajtmh.1998.58.461 Brieger, 2011, Compliance with eight years of annual ivermectin treatment of onchocerciasis in Cameroon and Nigeria, Parasit. Vectors, 4, 152, 10.1186/1756-3305-4-152 Brieger, 2015, The potential for community-directed interventions: reaching underserved populations in Africa, Int. Q.Community Health Educ., 35, 295, 10.1177/0272684X15592757 Buttner, 2003, Obligatory symbiotic Wolbachia endobacteria are absent from Loa loa, Filaria. J., 2, 10, 10.1186/1475-2883-2-10 Campbell, 2012, History of avermectin and ivermectin, with notes on the history of other macrocyclic lactone antiparasitic agents, Curr. Pharm. Biotechnol., 13, 853, 10.2174/138920112800399095 Ceballos, 2009, Flubendazole in cystic echinococcosis therapy: pharmaco-parasitological evaluation in mice, Parasitol. Int., 58, 354, 10.1016/j.parint.2009.07.006 Ceballos, 2014, Exploring the potential of flubendazole in filariasis control: evaluation of the systemic exposure for different pharmaceutical preparations, PLoS.Negl. Trop. Dis., 8, e2838, 10.1371/journal.pntd.0002838 Center for Disease Control (CDC), 2013, Progress toward elimination of onchocerciasis in the americas - 1993-2012, MMWR Morb.Mortal.Wkly.Rep, 62, 405 Churcher, 2009, Identifying sub-optimal responses to ivermectin in the treatment of River Blindness, Proc. Natl. Acad. Sci. U.S.A, 106, 16716, 10.1073/pnas.0906176106 Cline, 1992, Albendazole in the treatment of onchocerciasis: double-blind clinical trial in Venezuela, Am. J. Trop. Med. Hyg., 47, 512, 10.4269/ajtmh.1992.47.512 Coffeng, 2014, Elimination of African onchocerciasis: modeling the impact of increasing the frequency of ivermectin mass treatment, PLoS.One, 9, e115886, 10.1371/journal.pone.0115886 Coffeng, 2013, African Programme for Onchocerciasis Control 1995-2015: model-estimated health impact and cost, PLoS.Negl. Trop. Dis., 7, e2032, 10.1371/journal.pntd.0002032 Coffeng, 2014, African programme for onchocerciasis control 1995-2015: updated health impact estimates based on new disability weights, PLoS.Negl. Trop. Dis., 8, e2759, 10.1371/journal.pntd.0002759 Cole, 2010, Accelerating drug development and approval, Drug News Perspect., 23, 37, 10.1358/dnp.2010.23.1.1441464 Congress of the United States - Congressional Budget Office, 2006 Convit, 2013, Interruption of onchocerca volvulus transmission in northern Venezuela, Parasit. Vectors, 6, 289, 10.1186/1756-3305-6-289 Cotreau, 2003, The antiparasitic moxidectin: safety, tolerability, and pharmacokinetics in humans, J. Clin. Pharmacol., 43, 1108, 10.1177/0091270003257456 Crisford, 2015, The cyclooctadepsipeptide anthelmintic emodepside differentially modulates nematode, insect and human calcium-activated potassium (SLO) channel alpha subunits, PLoS.Negl. Trop. Dis., 9, e0004062, 10.1371/journal.pntd.0004062 D’Ambrosio, 2015, Point-of-care quantification of blood-borne filarial parasites with a mobile phone microscope, Sci. Transl. Med., 7, 286re4, 10.1126/scitranslmed.aaa3480 Dadzie, 2003, Final report of the conference on the eradicability of Onchocerciasis, Filaria. J., 2, 2, 10.1186/1475-2883-2-2 Debrah, 2006, Assessment of microfilarial loads in the skin of onchocerciasis patients after treatment with different regimens of doxycycline plus ivermectin, Filaria. J., 5, 1, 10.1186/1475-2883-5-1 Debrah, 2015, Doxycycline leads to sterility and enhanced killing of female Onchocerca volvulus worms in an area with persistent microfilaridermia after repeated ivermectin treatment: a randomized, placebo-controlled, double-blind trial, Clin. Infect. Dis., 61, 517, 10.1093/cid/civ363 DeSole, 1989, A community trial of ivermectin in the onchocerciasis focus of Asubende, Ghana. II. Adverse reactions, Trop. Med. Parasitol., 40, 375 DeSole, 1989, Adverse reactions after large-scale treatment of onchocerciasis with ivermectin: combined results from eight community trials, Bull. World Health Organ, 67, 707 Diawara, 2009, Feasibility of onchocerciasis elimination with ivermectin treatment in endemic foci in Africa: first evidence from studies in Mali and Senegal, PLoS.Negl. Trop. Dis., 3, e497, 10.1371/journal.pntd.0000497 Dimasi, 2003, The price of innovation: new estimates of drug development costs, J.Health Econ., 22, 151, 10.1016/S0167-6296(02)00126-1 Dominguez-Vazquez, 1983, Comparison of flubendazole and diethylcarbamazine in treatment of onchocerciasis, Lancet, 1, 139, 10.1016/S0140-6736(83)92753-8 Duke, 1991, Observations and reflections on the immature stages of Onchocerca volvulus in the human host, Ann. Trop. Med. Parasitol., 85, 103, 10.1080/00034983.1991.11812536 Epe, 2013, New advancement in anthelmintic drugs in veterinary medicine, Trends Parasitol., 29, 129, 10.1016/j.pt.2013.01.001 Fobi, 2015, Managing the fight against onchocerciasis in Africa: APOC experience, PLoS.Negl. Trop. Dis., 9, e0003542, 10.1371/journal.pntd.0003542 Food and Drug Administration of the United States of America, 2012 Francis, 1985, The Mazzotti reaction following treatment of onchocerciasis with diethylcarbamazine: clinical severity as a function of infection intensity, Am. J. Trop. Med. Hyg., 34, 529, 10.4269/ajtmh.1985.34.529 Fulford, 1987, The chemotherapy of onchocerciasis. XII. The prediction of microfilarial loads in patients with onchocerciasis after treatment with diethylcarbamazine in northern Ghana, Ann. Trop. Med. Parasitol., 81, 701, 10.1080/00034983.1987.11812173 Gardon, 1997, Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection, Lancet, 350, 18, 10.1016/S0140-6736(96)11094-1 Genchi, 1998, Preliminary results on the effect of tetracycline on the embryogenesis and symbiotic bacteria (Wolbachia) of Dirofilaria immitis. An update and discussion, Parassitologia, 40, 247 Grobusch, 2003, No evidence of Wolbachia endosymbiosis with Loa loa and Mansonella perstans, Parasitol. Res., 90, 405, 10.1007/s00436-003-0872-z Harder, 2005, Mechanisms of action of emodepside, Parasitol. Res., 97, S1, 10.1007/s00436-005-1438-z Harder, 2003, Cyclooctadepsipeptides–an anthelmintically active class of compounds exhibiting a novel mode of action, Int. J.Antimicrob. Agents, 22, 318, 10.1016/S0924-8579(03)00219-X Harder, 2002, Cyclooctadepsipeptides–a new class of anthelmintically active compounds, Parasitol. Res., 88, 481, 10.1007/s00436-002-0619-2 Haselow, 2003, Programmatic and communication issues in relation to serious adverse events following ivermectin treatment in areas Co-endemic for onchocerciasis and loiasis, Filaria. J., 2, S10, 10.1186/1475-2883-2-S1-S10 Higazi, 2013, Interruption of onchocerca volvulus transmission in the Abu Hamed focus, Sudan, Am. J. Trop. Med. Hyg., 89, 51, 10.4269/ajtmh.13-0112 Hoerauf, 2001, Depletion of wolbachia endobacteria in Onchocerca volvulus by doxycycline and microfilaridermia after ivermectin treatment, Lancet, 357, 1415, 10.1016/S0140-6736(00)04581-5 Hoerauf, 2003, Doxycycline in the treatment of human onchocerciasis: kinetics of Wolbachia endobacteria reduction and of inhibition of embryogenesis in female Onchocerca worms, Microbes. Infect., 5, 261, 10.1016/S1286-4579(03)00026-1 Hoerauf, 2008, Effects of 6-week azithromycin treatment on the Wolbachia endobacteria of Onchocerca volvulus, Parasitol. Res., 103, 279, 10.1007/s00436-008-0964-x Hoerauf, 2008, Wolbachia endobacteria depletion by doxycycline as antifilarial therapy has macrofilaricidal activity in onchocerciasis: a randomized placebo-controlled study, Med. Microbiol. Immunol., 197, 295, 10.1007/s00430-007-0062-1 Hoerauf, 2009, Efficacy of 5-week doxycycline treatment on adult Onchocerca volvulus, Parasitol. Res., 104, 437, 10.1007/s00436-008-1217-8 Hoerauf, 2000, Endosymbiotic bacteria in worms as targets for a novel chemotherapy in filariasis, Lancet, 355, 1242, 10.1016/S0140-6736(00)02095-X Horstick, 2010, Operational research in low-income countries, Lancet Infect. Dis., 10, 369, 10.1016/S1473-3099(10)70094-3 Horton, 2000, An analysis of the safety of the single dose, two drug regimens used in programmes to eliminate lymphatic filariasis, Parasitology, 121, S147, 10.1017/S0031182000007423 International Federation of Pharmaceutical Manufacturers & Associations, 2009 Johnston, 2014, Repurposing of approved drugs from the human pharmacopoeia to target Wolbachia endosymbionts of onchocerciasis and lymphatic filariasis, Int. J. Parasitol. Drugs Drug Resist, 4, 278, 10.1016/j.ijpddr.2014.09.001 Kamgno, 2016, Effect of two or six doses 800 mg of albendazole every two months on loa loa microfilaraemia: a double blind, randomized, placebo-controlled trial, PLoS.Negl. Trop. Dis., 10, e0004492, 10.1371/journal.pntd.0004492 Kanza, 2013, Opthalmological findings from a study comparing the effect of a single dose of 150 microgram/kg ivermectin and of 8 mg moxidectin on microfilariae levels in Onchocerca volvulus infections, Am. J. Trop. Med. Hyg., 89, 79 Kesselheim, 2015, Experience with the priority review voucher program for drug development, JAMA, 314, 1687, 10.1001/jama.2015.11845 Kola, 2004, Can the pharmaceutical industry reduce attrition rates?, Nat.Rev. Drug Discov., 3, 711, 10.1038/nrd1470 Korth-Bradley, 2013, Relative bioavailability of liquid and tablet formulations of the antiparasitic moxidectin, Clin. Pharmacol. Drug Dev., 1, 32, 10.1177/2160763X11432508 Korth-Bradley, 2012, The effect of a high-fat breakfast on the pharmacokinetics of moxidectin in healthy male subjects: a randomized phase I trial, Am. J. Trop. Med. Hyg., 86, 122, 10.4269/ajtmh.2012.11-0415 Korth-Bradley, 2011, Excretion of moxidectin into breast milk and pharmacokinetics in healthy lactating women, Antimicrob. Agents Chemother., 55, 5200, 10.1128/AAC.00311-11 Korth-Bradley, 2014, Effect of moxidectin on CYP3A4 activity as evaluated by oral midazolam pharmacokinetics in healthy subjects, Clin. Pharmacol. Drug Dev., 3, 151, 10.1002/cpdd.81 Kozek, 1977, Intracytoplasmic bacteria in Onchocerca volvulus, Am. J. Trop. Med. Hyg., 26, 663, 10.4269/ajtmh.1977.26.663 Krucken, 2012, Anthelmintic cyclcooctadepsipeptides: complex in structure and mode of action, Trends Parasitol., 28, 385, 10.1016/j.pt.2012.06.005 Kulke, 2014, Characterization of the Ca2+-gated and voltage-dependent K+-channel Slo-1 of nematodes and its interaction with emodepside, PLoS.Negl. Trop. Dis., 8, e3401, 10.1371/journal.pntd.0003401 Lamberton, 2015, Onchocerciasis transmission in Ghana: persistence under different control strategies and the role of the simuliid vectors, PLoS.Negl. Trop. Dis., 9, e0003688, 10.1371/journal.pntd.0003688 Longo, 2013, Effects of the benzimidazole anthelmintic drug flubendazole on rat embryos in vitro, Reprod. Toxicol., 36, 78, 10.1016/j.reprotox.2012.12.004 Longo, 2014, In vivo preliminary investigations of the effects of the benzimidazole anthelmintic drug flubendazole on rat embryos and fetuses, Reprod. Toxicol., 49C, 33, 10.1016/j.reprotox.2014.06.009 Lovato, 2014, Interruption of infection transmission in the onchocerciasis focus of Ecuador leading to the cessation of ivermectin distribution, PLoS.Negl. Trop. Dis., 8, e2821, 10.1371/journal.pntd.0002821 Lukiana, 2006, A possible case of spontaneous Loa loa encephalopathy associated with a glomerulopathy, Filaria. J., 5, 6, 10.1186/1475-2883-5-6 Mackenzie, 2011, Flubendazole: a candidate macrofilaricide for lymphatic filariasis and onchocerciasis field programs, Expert. Rev. Anti. Infect. Ther., 9, 497, 10.1586/eri.11.30 Mackenzie, 2003, Possible pathogenic pathways in the adverse clinical events seen following ivermectin administration to onchocerciasis patients, Filaria. J., 2, S5, 10.1186/1475-2883-2-S1-S5 Mackenzie, 2012, Elimination of onchocerciasis from Africa: possible?, Trends Parasitol., 28, 16, 10.1016/j.pt.2011.10.003 Mectizan Expert Committee and APOC Technical Consultative Committee, 2004 Nana-Djeunga, 2014, Reproductive status of Onchocerca volvulus after ivermectin treatment in an ivermectin-naive and a frequently treated population from Cameroon, PLoS.Negl. Trop. Dis., 8, e2824, 10.1371/journal.pntd.0002824 Noma, 2014, The geographic distribution of Onchocerciasis in the 20 participating countries of the African programme for Onchocerciasis control: (1) priority areas for ivermectin treatment, Parasit. Vectors, 7, 325, 10.1186/1756-3305-7-325 Nutman, 1986, Loa loa infection in temporary residents of endemic regions: recognition of a hyperresponsive syndrome with characteristic clinical manifestations, J. Infect. Dis., 154, 10, 10.1093/infdis/154.1.10 O’Hanlon, 2016, Model-based geostatistical mapping of the prevalence of onchocerca volvulus in West Africa, PLoS.Negl. Trop. Dis., 10, e0004328, 10.1371/journal.pntd.0004328 Olliaro, 2011, Potential drug development candidates for human soil-transmitted helminthiases, PLoS.Negl. Trop. Dis., 5, e1138, 10.1371/journal.pntd.0001138 Opoku, 2013, Efficacy of a single oral dose of 8 mg Moxidectin vs. 150 ug/kg ivermectin in onchocerca volvulus infection: results of a randomized, double-blind single dose phase 3 study in areas without mass treatment with ivermectin in Liberia, Ghana and DRC, Trop.Med.Int Health, 18, 58 Osei-Atweneboana, 2011, Phenotypic evidence of emerging ivermectin resistance in Onchocerca volvulus, PLoS.Negl. Trop. Dis., 5, e998, 10.1371/journal.pntd.0000998 Osei-Atweneboana, 2007, Prevalence and intensity of Onchocerca volvulus infection and efficacy of ivermectin in endemic communities in Ghana: a two-phase epidemiological study, Lancet, 369, 2021, 10.1016/S0140-6736(07)60942-8 Ozoh, 2011, The African Programme for Onchocerciasis Control: impact on onchocercal skin disease, Trop.Med.Int Health, 16, 875, 10.1111/j.1365-3156.2011.02783.x Pharmaceutical Research and Manufacturers of America, 2007 Pion, 2015, The impact of two semiannual treatments with albendazole alone on lymphatic filariasis and soil-transmitted helminth infections: a community-based study in the Republic of Congo, Am. J. Trop. Med. Hyg., 92, 959, 10.4269/ajtmh.14-0661 Pion, 2011, Individual host factors associated with Onchocerca volvulus microfilarial densities 15, 80 and 180 days after a first dose of ivermectin, Acta Trop., 120, S91, 10.1016/j.actatropica.2010.05.004 Pion, 2013, Dynamics of Onchocerca volvulus microfilarial densities after ivermectin treatment in an ivermectin-naive and a multiply treated population from Cameroon, PLoS.Negl. Trop. Dis., 7, e2084, 10.1371/journal.pntd.0002084 Plaisier, 1990, ONCHOSIM: a model and computer simulation program for the transmission and control of onchocerciasis, Comput. Methods Programs Biomed., 31, 43, 10.1016/0169-2607(90)90030-D Plaisier, 1991, The reproductive lifespan of Onchocerca volvulus in West African savanna, Acta Trop., 48, 271, 10.1016/0001-706X(91)90015-C Prichard, 2012, Moxidectin and the avermectins: consanguinity but not identity, Int. J. Parasitol. Drugs Drug Resist, 2, 134, 10.1016/j.ijpddr.2012.04.001 Remme, 1986, A force-of-infection model for onchocerciasis and its applications in the epidemiological evaluation of the Onchocerciasis Control Programme in the Volta River basin area, Bull. World Health Organ, 64, 667 Remme, 1989, A community trial of ivermectin in the onchocerciasis focus of Asubende, Ghana. I. Effect on the microfilarial reservoir and the transmission of Onchocerca volvulus, Trop. Med. Parasitol., 40, 367 Remme, 1990, The predicted and observed decline in onchocerciasis infection during 14 years of successful control of Simulium spp. in west Africa, Bull. World Health Organ, 68, 331 Remme, 2004, Research for control: the onchocerciasis experience, Trop.Med.Int. Health, 9, 243, 10.1046/j.1365-3156.2003.01192.x Richards, 2007, No depletion of Wolbachia from Onchocerca volvulus after a short course of rifampin and/or azithromycin, Am. J. Trop. Med. Hyg., 77, 878, 10.4269/ajtmh.2007.77.878 Ridley, 2006, Developing drugs for developing countries, Health Aff. (Millwood.), 25, 313, 10.1377/hlthaff.25.2.313 Ridley, 2010, Introduction of European priority review vouchers to encourage development of new medicines for neglected diseases, Lancet, 376, 922, 10.1016/S0140-6736(10)60669-1 Robertson, 2012, The impact of the US priority review voucher on private-sector investment in global health research and development, PLoS.Negl. Trop. Dis., 6, e1750, 10.1371/journal.pntd.0001750 Rodriguez-Perez, 2015, Elimination of onchocerciasis from Mexico, PLoS.Negl. Trop. Dis., 9, e0003922, 10.1371/journal.pntd.0003922 Roungou, 2015, 40 Years of the APOC partnership, PLoS.Negl. Trop. Dis., 9, e0003562, 10.1371/journal.pntd.0003562 Sachs-Barrable, 2014, The use of the United States FDA programs as a strategy to advance the development of drug products for neglected tropical diseases, Drug Dev. Ind. Pharm., 40, 1429, 10.3109/03639045.2014.884132 Scientific Working Group on Serious Adverse Events in Loa Loa endemic areas, 2003, Report of a scientific working group on serious adverse events following Mectizan(R) treatment of onchocerciasis in loa loa endemic areas, Filaria. J., 2, S2 Sommerfeld, 2015, Applied research for better disease prevention and control, PLoS.Negl. Trop. Dis., 9, e3378, 10.1371/journal.pntd.0003378 Sonderholm, 2009, In defence of priority review vouchers, Bioethics, 23, 413, 10.1111/j.1467-8519.2009.01753.x Specht, 2008, Efficacy of 2- and 4-week rifampicin treatment on the Wolbachia of Onchocerca volvulus, Parasitol. Res., 103, 1303, 10.1007/s00436-008-1133-y Stolk, 2015, Required duration of mass ivermectin treatment for onchocerciasis elimination in Africa: a comparative modelling analysis, Parasit. Vectors, 8, 552, 10.1186/s13071-015-1159-9 Tagboto, 1996, Onchocerca volvulus and O. lienalis: the microfilaricidal activity of moxidectin compared with that of ivermectin in vitro and in vivo, Ann. Trop. Med. Parasitol., 90, 497, 10.1080/00034983.1996.11813075 Tamarozzi, 2011, Onchocerciasis: the role of Wolbachia bacterial endosymbionts in parasite biology, disease pathogenesis, and treatment, Clin. Microbiol. Rev., 24, 459, 10.1128/CMR.00057-10 Taylor, 2000, Wolbachia bacteria of filarial nematodes: a target for control?, Parasitol. Today, 16, 179, 10.1016/S0169-4758(00)01661-6 Taylor, 2014, Anti-Wolbachia drug discovery and development: safe macrofilaricides for onchocerciasis and lymphatic filariasis, Parasitology, 141, 119, 10.1017/S0031182013001108 Tekle, 2012, Impact of long-term treatment of onchocerciasis with ivermectin in Kaduna State, Nigeria: first evidence of the potential for elimination in the operational area of the African Programme for Onchocerciasis Control, Parasit. Vectors, 5, 28, 10.1186/1756-3305-5-28 Townson, 2005, Activity of the cyclooctadepsipeptide emodepside against onchocerca gutturosa, onchocerca lienalis and brugia pahangi, Am. J. Trop. Med. Hyg., 73, 93 Traore, 2012, Proof-of-principle of onchocerciasis elimination with ivermectin treatment in endemic foci in Africa: final results of a study in Mali and Senegal, PLoS.Negl. Trop. Dis., 6, e1825, 10.1371/journal.pntd.0001825 Turner, 2013, Uncertainty surrounding projections of the long-term impact of ivermectin treatment on human onchocerciasis, PLoS.Negl. Trop. Dis., 7, e2169, 10.1371/journal.pntd.0002169 Turner, 2015, The potential impact of moxidectin on onchocerciasis elimination in Africa: an economic evaluation based on the Phase II clinical trial data, Parasit. Vectors, 8, 167, 10.1186/s13071-015-0779-4 Turner, 2014, Modelling the impact of ivermectin on River Blindness and its burden of morbidity and mortality in African Savannah: EpiOncho projections, Parasit. Vectors, 7, 241, 10.1186/1756-3305-7-241 Turner, 2010, Macrofilaricidal activity after doxycycline only treatment of Onchocerca volvulus in an area of Loa loa co-endemicity: a randomized controlled trial, PLoS.Negl. Trop. Dis., 4, e660, 10.1371/journal.pntd.0000660 Tweats, 2016, Genotoxicity of flubendazole and its metabolites in vitro and the impact of a new formulation on in vivo aneugenicity, Mutagenesis, 31, 309, 10.1093/mutage/gev070 Twum-Danso, 2003, Loa loa encephalopathy temporally related to ivermectin administration reported from onchocerciasis mass treatment programs from 1989 to 2001: implications for the future, Filaria. J., 2, S7, 10.1186/1475-2883-2-S1-S7 Twum-Danso, 2003, Serious adverse events following treatment with ivermectin for onchocerciasis control: a review of reported cases, Filaria. J., 2, S3, 10.1186/1475-2883-2-S1-S3 Twum-Danso, 2003, Variation in incidence of serious adverse events after onchocerciasis treatment with ivermectin in areas of Cameroon co-endemic for loiasis, Trop.Med.Int Health, 8, 820, 10.1046/j.1365-3156.2003.01091.x von Samson-Himmelstjerna, 2005, Efficacy of two cyclooctadepsipeptides, PF1022A and emodepside, against anthelmintic-resistant nematodes in sheep and cattle, Parasitology, 130, 343, 10.1017/S0031182004006523 Walker, 2015, Therapeutic efficacy and macrofilaricidal activity of doxycycline for the treatment of river blindness, Clin. Infect. Dis., 60, 1199, 10.1093/cid/ciu1152 Wanji, 2015, Situation analysis of parasitological and entomological indices of onchocerciasis transmission in three drainage basins of the rain forest of South West Cameroon after a decade of ivermectin treatment, Parasit. Vectors, 8, 202, 10.1186/s13071-015-0817-2 West, 2013, River blindness eliminated in Colombia, Ophthalmic Epidemiol., 20, 258, 10.3109/09286586.2013.836230 WHO/TDR, 2005 Willson, 2003, The effect of the anthelmintic emodepside at the neuromuscular junction of the parasitic nematode Ascaris suum, Parasitology, 126, 79, 10.1017/S0031182002002639 World Health Organization, 1995 World Health Organization, 2012 World Health Organization, 2012 World Health Organization, 2016 Zarroug, 2014, The impact of Merowe dam on Simulium hamedense vector of onchocerciasis in Abu Hamed focus - northern Sudan, Parasit. Vectors, 7, 168, 10.1186/1756-3305-7-168 Zoure, 2014, The geographic distribution of onchocerciasis in the 20 participating countries of the African Programme for Onchocerciasis control: (2) pre-control endemicity levels and estimated number infected, Parasit. Vectors, 7, 326, 10.1186/1756-3305-7-326 Zoure, 2011, The geographic distribution of Loa loa in Africa: results of large-scale implementation of the Rapid Assessment Procedure for Loiasis (RAPLOA), PLoS.Negl. Trop. Dis., 5, e1210, 10.1371/journal.pntd.0001210